NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
24 hedge funds and large institutions have $371K invested in NeuBase Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
17% less funds holding
Funds holding: 29 → 24 (-5)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
63% less capital invested
Capital invested by funds: $991K → $371K (-$620K)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$80K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$31.4K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$13.8K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$10.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$246K |
| 2 |
GBA
Garrison Bradford & Associates
New York
|
-$55.8K |
| 3 |
VF
Virtu Financial
New York
|
-$11K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$9K |
| 5 |
BMCM
Bryn Mawr Capital Management
Philadelphia,
Pennsylvania
|
-$3K |
NBSE Hedge Fund Activity: Q4 2018 in Review
24 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2018, worth a combined $371K — down 63% from $991K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NBSE and 1 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $80K. The largest seller was Vanguard Group, cutting an estimated $246K.
- 24 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2018, down from 29 in Q3 2018.
- Funds reported $371K of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2018, down 63% quarter-over-quarter.
- 1 fund opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2018 and 6 closed out, a net change of -5 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $80K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $246K sold.
Based on aggregated 13F filings for Q4 2018.